US7314859B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
Assignee: DiObex Inc
•
Filing: 2003-12-23
•
Granted: 2008-01-01
•
Expires: 2023-12-23
Abstract
Abstract Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.
Inventors
- 👤 Daniel T Green
- 👤 Robert R. Henry
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 09:18
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/26; A61K31/00; A61K31/21; A61K31/26; A61K38/28; A61K9/00; A61P; A61P3/00; A61P3/08; A61P3/10; A61P43/00; A61K9/0012; A61K9/0014; A61K9/0019; A61K9/007; A61K9/0073; A61K9/0075; A61K9/008
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
98 words
A method of reducing the risk of insulin-induced htpoglycemia in a diabetes patient who is being treated with insulin, which method comprises administering to the patient an amount of glucagon that results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 5.00 ng/kg/min, wherein glucagon is administered daily as part of a diabetes treatment regimen, and wherein said patient is not suffering hypoglycemic symptoms and has a blood glucose level of from 70-110 mg/dL when said glucagon is administered.
Claim 2
Independent Claim
98 words
A method of reducing the risk of insulin-induced htpoglycemia in a diabetes patient who is being treated with insulin, which method comprises administering to the patient an amount of glucagon that results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 5.00 ng/kg/min, wherein glucagon is administered daily as part of a diabetes treatment regimen, and wherein said patient is not suffering hypoglycemic symptoms and has a blood glucose level of from 70-110 mg/dL when said glucagon is administered.
Claim 3
Dependent Claim
28 words
The method of claim 1 , wherein said glucagon is administered simultaneously with, or within one minute to four hours after said patient has last been administered insulin.
Claim 4
Dependent Claim
19 words
The method of claim 1 , wherein said glucagon is administered parenterally by a subcutaneous, intramuscular, or intravenous route.
Claim 5
Dependent Claim
18 words
The method of claim 3 , wherein said glucagon is a glucagon with a longer duration of action.
Claim 6
Dependent Claim
15 words
The method of claim 3 , wherein said glucagon is contained in a liposomal formulation.
Claim 7
Dependent Claim
14 words
The method of claim 3 , wherein said glucagon is contained in a microsphere.
Claim 8
Dependent Claim
41 words
The method of claim 1 wherein the administration of glucagon results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 3.00 ng/kg/min.
Claim 9
Dependent Claim
12 words
The method of claim 1 wherein glucagon is administered daily at bedtime.
References Cited (Backward Citations)
GB748857A
Cited
GB766994A
Cited
GB766995A
Cited
US2902408A
Cited
GB831907A
Cited
GB844434A
Cited
US3897551A
Cited
US4003379A
Cited
US4498843A
Cited
US4633878A
Cited
US4492684A
Cited
US4538616A
Cited
US4826763A
Cited
US5237993A
Cited
WO1988009341A1
Cited
EP0300552A1
Cited
US4839174A
Cited
US4943435A
Cited
US5101814A
Cited
US5190041A
Cited
US5234903A
Cited
US5542935A
Cited
EP0442724A2
Cited
US5643607A
Cited
US5643604A
Cited
US6103233A
Cited
US5321008A
Cited
US5234906A
Cited
US5508260A
Cited
US5527771A
Cited
US5656590A
Cited
US5814600A
Cited
US5445832A
Cited
US5637568A
Cited
US6284727B1
Cited
US5359030A
Cited
EP1264837A1
Cited
US6191105B1
Cited
US6114304A
Cited
US6703365B2
Cited
US20020119146A1
Cited
EP0684044A2
Cited
US5474552A
Cited
US5707641A
Cited
EP0816381A1
Cited
US5869602A
Cited
US20010016643A1
Cited
WO1997003688A1
Cited
US5849322A
Cited
US5741211A
Cited
WO1997024440A1
Cited
US6348214B1
Cited
US6197333B1
Cited
US6239107B1
Cited
US6277863B1
Cited
WO1998008871A1
Cited
WO1998031383A1
Cited
US6217893B1
Cited
US5919216A
Cited
US6135978A
Cited
US6093167A
Cited
US6573238B2
Cited
US6500918B2
Cited
WO1999043708A1
Cited
US6107489A
Cited
US6589548B1
Cited
US6566490B1
Cited
US20020115592A1
Cited
US20020114829A1
Cited
US6520326B2
Cited
US6261280B1
Cited
US6559122B1
Cited
US6319510B1
Cited
US6593295B2
Cited
US6329336B1
Cited
US6461331B1
Cited
US20030108568A1
Cited
US20020026141A1
Cited
WO2001054742A1
Cited
US20010033858A1
Cited
US6572542B1
Cited
WO2001082874A2
Cited
WO2001082981A1
Cited
WO2002022154A2
Cited
WO2002032957A1
Cited
WO2002043566A2
Cited
WO2002046227A2
Cited
US20040110817A1
Cited
WO2004060387A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2010-12-31 | 2011-07-02 | 2012-01-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2014-12-31 | 2015-07-02 | 2016-01-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2018-12-31 | 2019-07-02 | 2020-01-01 | $7700.00 | Window Closed / Lapsed |